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CorrespondenceIntegron attI1 Sites, Not
Riboswitches, Associate with
Antibiotic Resistance GenesIn a recent publication in Cell (Jia et al.,
2013), the authors conclude from bioin-
formatics, genetic, and biochemical ana-
lyses that a conserved sequence element
associated with antibiotic resistance
genes represents a novel widespread
riboswitch class for certain aminoglyco-
sides. Below, we point out previously re-
ported functions for this element that
were not discussed by the authors, and
we note other issues with the validation
experiments that raise significant con-
cerns about the conclusions of the study.
Most riboswitches contain highly
conserved ligand-binding domains, and
therefore the identification of consensus
sequence and structure models is critical
in providing support for proposed ribos-
witch classes. Jia et al. describe a
conserved sequence element that is
frequently associated with aminoglyco-
side acetyl transferase (aac) and amino-
glycoside adenyl transferase (aad) genes,
and they ultimately conclude that it cor-
responds to mRNA leader sequences
with riboswitch functions. However, the
consensus sequence that they describe
was already known to be a key com-
ponent of integrons, serving as a recom-
bination site (attI) that facilitates the
exchange of gene cassettes sometimes
involved in antibiotic resistance (Mazel,
2006).
Sequences in their alignment (Data S1)
correspond specifically to the attI1 class
of recombination sites (Partridge et al.,
2000), and the locations of these sites—
within class 1 integrons, between the
intI1 gene encoding the integrase and
the integron cassettes—are consistent
with a function in recombination. Impor-
tantly, the most highly conserved seg-
ments in the alignment, which contain
the sequence defined by the authors as
the riboswitch aptamer domain, precisely
encompass the regions of the attI1 DNA
that interact with the integrase and that
are necessary for recombination to occur
(Recchia et al., 1994; Collis et al., 1998;Gravel et al., 1998). Moreover, there are
no segments other than those corre-
sponding to the attI1 site that are uni-
versally conserved among the aligned
sequences. Thus, if these sequences
also function at the level of RNA as amino-
glycoside riboswitches (in addition to their
known functions at the DNA level as
specialized recombination sites), the
conserved domains responsible for each
independent function would have to be
perfectly coincident.
Although Jia et al. mention in the
Discussion that their reported sequences
are ‘‘constituent(s) of the integron
cassette system,’’ they never state that
these sites have biochemical functions
that were already well understood. Given
the previously established function of
this element, it seems unlikely that the
conserved nucleotides are also important
for riboswitch function. This concern is
reinforced by the fact that the locations
of attI1 sequences are not limited to re-
gions near aminoglycoside resistance
genes, as implied by the data depicted
in Figure 1C. Integrons containing attI1
sites commonly contain gene cassettes
involved in resistance to a wide range of
antibiotics, including trimethoprim, rifam-
picin, chloramphenicol, tetracycline,
erythromycin, sulfonamides, quinolones,
quaternary ammonium compounds, and
various b-lactams (Moura et al., 2009). It
seems counterintuitive for the optimal
expression of these myriad antibiotic
resistance genes to be contingent on the
function of a riboswitch that responds
only to a limited number of aminoglyco-
side derivatives.
In addition, there are numerous
instances of aminoglycoside resistance
genes occurring in contexts apart from
integrons, many examples of which are
listed by the authors in Table S1A.
In such instances, the aminoglycoside
resistance genes are never observed to
be associated with attI1 sites. It is only
when these genes are contained withinCell 15integrons that attI1 sites are present.
This strict association of attI1 sequences
with integrons, rather than with aminogly-
coside resistance genes, provides further
evidence that these elements function
exclusively in their known capacity as
integron components and not as amino-
glycoside riboswitches.
In light of the previously defined role of
attI1 sites, interpretations of the authors’
biochemical and genetic data should be
assessed more cautiously. As the authors
note, the cationic amino groups of amino-
glycosides result in a propensity for bind-
ing interactions with polyanionic RNA.
Several reports have demonstrated that
specific aminoglycosides have pro-
nounced effects on the activities and
structures of various RNAs (e.g., see
Hermann and Westhof, 1999). In many of
these examples, however, the interaction
between the antibiotic and the target
RNA is presumed not to be biologically
relevant. Such studies underscore the
hazards of imputing biological signifi-
cance to interactions in vitro between
RNA and aminoglycosides and suggest
that the binding assays of Jia et al. likely
reflect spurious interactions. Consistent
with this possibility is the fact that the
most prominent site of aminoglycoside-
dependent structure modulation ob-
served by the authors (SD2, Figure 3C)
occurs outside of the attI1 sequence in
one of the least conserved regions of their
sequence alignment.
Jia et al. also prepared genetic fusions
between the attI1 DNA sequence and a
b-galactosidase gene and observe 1.5-
to 2.5-fold increases in gene expression
in response to antibiotics such as kana-
mycin B and sisomycin. However, these
increases are exceedingly modest com-
pared to the more typical 10- to 1,000-
fold dynamic ranges for gene regulation
achieved by known riboswitches. More-
over, these aminoglycoside antibiotics
function by targeting ribosomes, which
will inherently alter global protein produc-
tion and therefore could easily cause
small changes in reporter gene expres-
sion bymechanisms that are independent
of a riboswitch. Although the authors con-
ducted experiments intended to rule out a
ribosome-based mechanism for the gene
expression changes that they observe,
the resulting data from these experiments
are more easily explained by antibiotics3, June 20, 2013 ª2013 Elsevier Inc. 1417
binding to ribosomes instead of a ribos-
witch.
The authors propose a model in which
an RNA containing the attI1 sequence
undergoes a conformational change in
response to specific aminoglycosides,
resulting in increased levels of translation
from the unmasked Shine-Dalgarno
sequence (SD2). They also note
(Figure 7B) that an ORF potentially encod-
ing a short leader peptide overlaps the
attI1 sequence. Although it is not stated
by the authors, this ORF is a feature of
attI1 sites that was reported previously
(Hanau-Berc¸ot et al., 2002). This coding
region, termed ORF-11, functions to
enhance the expression at the transla-
tional level of antibiotic resistance genes
within class 1 integrons, probably by re-
cruiting ribosomes to cassette sequences
with deficient translation initiation regions.
This earlier work also demonstrated that
the efficacy of ORF-11 depends on its
translation, but not on the sequence of
the leader peptide.
Indeed, the mutational analysis of Jia
et al. (Figures 5A and 5B) is entirely
consistent with the gene control mecha-
nism proposed by Hanau-Berc¸ot et al.
(2002). Changes in the attI1 sequence
that interfere with translation of the leader
peptide (M1, M2, M3) result in 4- to 6-fold
decreases in expression of the b-galac-
tosidase reporter gene. Moreover,
sequences containing deletions that
maintain the reading frame of the leader
peptide (M9, M14, M15, M16) generate
only 2-fold reductions in reporter gene
expression, even when these deletions
result in the elimination of as many as
nine nucleotides from a highly conserved
domain of the attI1 RNA. In contrast, a
deletion in the same region that alters
the reading frame (M19) yields a 20-fold1418 Cell 153, June 20, 2013 ª2013 Elsevierreduction in b-galactosidase expression.
Collectively, these data offer considerably
more support for the model of Hanau-
Berc¸ot et al. (2002), in which the enhance-
ment in gene expression is derived from
translation of the leader peptide, than for
the model of Jia et al., which posits a
riboswitch mechanism.
The authors also designed threemutant
attI1 sequences (M23, M24, M25), each
containing several conservative muta-
tions that maintain the sequence of the
leader peptide (Figure 7B). Constructs
bearing these mutations generated sub-
stantial reductions in reporter gene
expression as compared with levels
generated by the wild-type sequence
(Figure 7C). Jia et al. conclude from these
experiments that high levels of gene
expression are driven by the sequence
of the attI1 RNA rather than by that of
the leader peptide. The interpretation of
this experiment is confounded, however,
because each of the three mutants bears
an additional point mutation that is not
present in the wild-type control, occurring
two nucleotides upstream of the leader
peptide initiation codon. This mutation
(C11A), which is not discussed by the
authors, creates a run of five consecutive
purine residues that could potentially
function as a decoy SD sequence and
disrupt normal expression of the leader
peptide. Even if this is not the case, it is
possible that a mutation in this region
could result in decreased translation of
the leader peptide and therefore might
account for the reduced b-galactosidase
levels in a manner consistent with the
model of Hanau-Berc¸ot et al. (2002).
Considering that the roles of attI1
sequences (both as class 1 integron
recombination sites and as translational
enhancers) have been previously estab-Inc.lished, that the data in Jia et al. are consis-
tent with these functions, and that there
are hundreds of known examples of attI1
sites positioned immediately upstream
of genes conferring resistance to structur-
ally diverse classes of antibiotics, readers
should be circumspect in evaluating the
authors’ claim that these sequences func-
tion as components of aminoglycoside-
specific riboswitches.
Adam Roth1,*
and Ronald R. Breaker1,2,3,*
1Howard Hughes Medical Institute
2Department of Molecular, Cellular,
and Developmental Biology
3Department of Molecular Biophysics
and Biochemistry
Yale University, Box 208103, New Haven,
CT 06520, USA
*Correspondence: adam.roth@yale.edu
(A.R.), ronald.breaker@yale.edu (R.R.B.)
http://dx.doi.org/10.1016/j.cell.2013.05.043REFERENCES
Collis, C.M., Kim, M.J., Stokes, H.W., and Hall,
R.M. (1998). Mol. Microbiol. 29, 477–490.
Gravel, A., Fournier, B., and Roy, P.H. (1998).
Nucleic Acids Res. 26, 4347–4355.
Hanau-Berc¸ot, B., Podglajen, I., Casin, I., and
Collatz, E. (2002). Mol. Microbiol. 44, 119–130.
Hermann, T., and Westhof, E. (1999). J. Med.
Chem. 42, 1250–1261.
Jia, X., Zhang, J., Sun, W., He, W., Jiang, H., Chen,
D., and Murchie, A.I.H. (2013). Cell 152, 68–81.
Mazel, D. (2006). Nat. Rev. Microbiol. 4, 608–620.
Moura, A., Soares, M., Pereira, C., Leita˜o, N., Hen-
riques, I., and Correia, A. (2009). Bioinformatics 25,
1096–1098.
Partridge, S.R., Recchia, G.D., Scaramuzzi, C.,
Collis, C.M., Stokes, H.W., and Hall, R.M. (2000).
Microbiology 146, 2855–2864.
Recchia, G.D., Stokes, H.W., and Hall, R.M. (1994).
Nucleic Acids Res. 22, 2071–2078.
